{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:27Z","timestamp":1790960787910,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1209-1","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T13:04:11Z","timestamp":1552482251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Shubhadeep D.","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi Krishna","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Reddy","family":"Bheemareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa","family":"Chary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikranth Reddy","family":"Pinnamareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhramanyam","family":"Sreepada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Durugkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"1209_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1111\/j.1523-1755.2005.09403.x","volume":"67","author":"R Atkins","year":"2005","unstructured":"Atkins R. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;67:S14\u20138.","journal-title":"Kidney Int Suppl"},{"key":"1209_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00041552-200303000-00003","volume":"12","author":"D Robert","year":"2003","unstructured":"Robert D, Walter HH. Anemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2003;12:139\u201343.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1209_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1053\/ajkd.2001.26111","volume":"38","author":"S Donnelly","year":"2001","unstructured":"Donnelly S. Why is erythropoietin made in kidney? The kidney functions as a critmeter. Am J Kidney Dis. 2001;38:415\u201325.","journal-title":"Am J Kidney Dis"},{"issue":"5 Suppl 3","key":"1209_CR4","first-page":"S11","volume":"47","author":"KF National","year":"2006","unstructured":"National KF. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2215\/CJN.01170905","volume":"2","author":"BD Bradbury","year":"2007","unstructured":"Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol. 2007;2(1):89\u201399.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"1209_CR6","first-page":"i9","volume":"2","author":"C Fernando","year":"2009","unstructured":"Fernando C, Michel B. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2(Suppl 1):i9\u2013i17.","journal-title":"NDT Plus"},{"issue":"3","key":"1209_CR7","first-page":"433","volume":"3","author":"F Locatelli","year":"2007","unstructured":"Locatelli F, Pozzoni P, Del Vecchio L. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag. 2007;3(3):433.","journal-title":"Ther Clin Risk Manag"},{"issue":"suppl_8","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"viii13","DOI":"10.1093\/ndt\/gfh1111","volume":"20","author":"J Portol\u00e9s","year":"2005","unstructured":"Portol\u00e9s J, Krisper P, Choukroun G, de Francisco AL. Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients. Nephrol Dial Transplant. 2005;20(suppl_8):viii13\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1209_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/CEOR.S46930","volume":"6","author":"H Schmid","year":"2014","unstructured":"Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. ClinicoEconomics and outcomes research: CEOR. 2014;6:319.","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"issue":"20","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1440-1797.2002.00133.x","volume":"7","author":"Amgen Anaemia Advisory Group","year":"2002","unstructured":"Amgen Anaemia Advisory Group. Darbepoetin alfa: a new erythropoietic drug for the treatment of renal anaemia. Nephrology. 2002;7(6):315\u201323.","journal-title":"Nephrology"},{"key":"1209_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/ajkd.2002.33919","volume":"40","author":"AR Nissenson","year":"2002","unstructured":"Nissenson AR, Swan SK, Lindberg JS. Randomized, controlled trial of darbepoetin for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110\u20138.","journal-title":"Am J Kidney Dis"},{"key":"1209_CR13","unstructured":"Mehta KS, Sinha SD, Bandi Vamsi, Bala Reddy, Naidu NR, Thakur PA, et al. Darbepoetin alfa versus erythropoietin alfa for treatment of renal anemia in patients with chronic kidney disease at the pre-dialysis stage: a randomized non-inferiority trial. J Assoc Physicians India. 2019;67:62\u201366."}],"updated-by":[{"DOI":"10.1186\/s12882-019-1515-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000}}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1209-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1209-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1209-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:10:29Z","timestamp":1583971829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1209-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1209-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12882-019-1515-7","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors reported errors in the presentation of Tables 2, 4 and 5.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical guidelines outlined in the Declaration of Helsinki, 1964 as revised in 2013. Institutional ethics committee approval was obtained (details given in the Additional\u00a0file\u00a0: Table S1) from each participating study center before initiating the study. Prior to conducting any study-related screening procedure, written informed consent was obtained from each patient before enrolling them in the study. The study was registered with the clinical trial registry (CTRI: CTRI\/2012\/07\/002835) prior to any enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SS1, VB, BB, PT and SC are the employees of Hetero Biopharma Limited, India and involved from conception of study to the approval of the manuscript. All the authors declare no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"90"}}